<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423199</url>
  </required_header>
  <id_info>
    <org_study_id>NCCH1607</org_study_id>
    <secondary_id>WI217662</secondary_id>
    <nct_id>NCT03423199</nct_id>
  </id_info>
  <brief_title>PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY</brief_title>
  <acronym>PATHWAY</acronym>
  <official_title>Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the benefit of adding palbociclib in hormone receptor
      (HR)-positive, HER2-negative advanced or metastatic breast cancer patients, regardless of
      menopausal status, treated with tamoxifen (with or without goserelin) versus tamoxifen alone
      (with or without goserelin).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>The time from the date of randomization to the date of the first documentation of objective progression of disease (PD), clinically diagnosed symptomatic deterioration, or death due to any cause in the absence of documented PD, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the randomization of the last patient up to 3 years</time_frame>
    <description>The time from date of randomization to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Probabilities at 1 year, 2 year, and 3 year</measure>
    <time_frame>From the randomization of the last patient up to 3 years</time_frame>
    <description>The probability of survival 1 year, 2 or 3 years after the date of randomization based on the Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) ver.1.1 recorded from randomization until disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>The time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Response (CBR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>CR or PR or SD &gt;=24 weeks according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between Treatment Comparison in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scale Scores</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from &quot;not at all&quot; to &quot;very much&quot; and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between Treatment Comparison in European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Functional Scale Scores</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from 'not at all' to 'very much'. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentrations of palbociclib</measure>
    <time_frame>Cycle 1/Day 15 and Cycle 2/Day 15</time_frame>
    <description>Ctrough for palbociclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentrations of tamoxifen, 4-hydroxytamoxifen, N-desmethyltamoxifen and endoxifen</measure>
    <time_frame>Cycle 2/Day 15 and Cycle 3/Day 15</time_frame>
    <description>Ctrough for tamoxifen, 4-hydroxytamoxifen, N-desmethyltamoxifen and endoxifen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>From the first dose of the investigational product until 28 days after the last dose of study drugs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Palbociclib + Tamoxifen ± Goserelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Tamoxifen ± Goserelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment</description>
    <arm_group_label>Palbociclib + Tamoxifen ± Goserelin</arm_group_label>
    <other_name>PD-0332991</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment</description>
    <arm_group_label>Placebo + Tamoxifen ± Goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Tamoxifen, 20mg, orally once daily (continuously)</description>
    <arm_group_label>Palbociclib + Tamoxifen ± Goserelin</arm_group_label>
    <arm_group_label>Placebo + Tamoxifen ± Goserelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks</description>
    <arm_group_label>Palbociclib + Tamoxifen ± Goserelin</arm_group_label>
    <arm_group_label>Placebo + Tamoxifen ± Goserelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18 years of age or older with histologically or cytologically proven locally
             advanced or metastatic breast cancer, not amenable to resection or radiation therapy
             with curative intent

          -  Documented diagnosis of HR+/HER2- breast cancer

          -  Any menopausal status

          -  Previously untreated with any endocrine therapy for their HR+/HER2- advanced breast
             cancer; or progressed while on or within 3 month from prior endocrine therapy other
             than tamoxifen for advanced breast cancer. If patients have adjuvant endocrine
             therapy, they must satisfy as follows: progressed 12 months or more since prior
             adjuvant endocrine therapy with tamoxifen; or progressed during or after adjuvant
             endocrine therapy with an aromatase inhibitor.

          -  Measurable disease or non-measurable disease as defined by RECIST ver.1.1

          -  Eastern Cooperative Oncology Group (ECOG) PS 0-1

          -  Adequate organ and marrow function, resolution of all toxic effects of prior therapy
             or surgical procedures

        Exclusion Criteria:

          -  Prior treatment with any CDK inhibitor, tamoxifen, everolimus, or agent that inhibits
             the PI3K-mTOR pathway

          -  Patients with extensive advanced/metastatic, symptomatic visceral disease, or known
             uncontrolled or symptomatic CNS metastases

          -  Use of strong or moderate CYP3A4 and/or CYP2D6 inhibitors or inducers

          -  Major surgery or any anti-cancer therapy within 2 weeks of randomization

          -  Prior stem cell or bone marrow transplantation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenji Tamura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Breast and Medical Oncology, National Cancer Center Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomomi Hata, CCRP</last_name>
    <phone>+81-3-3542-2511</phone>
    <email>NCCH1607_office@ml.res.ncc.go.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroji Iwata, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirofumi Mukai, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>7910280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenjiro Aogi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0030804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masato Takahashi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>6738558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Matsumoto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>2418515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshinari Yamashita, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Ōsaka-sayama</city>
        <state>Osaka</state>
        <zip>5898511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junji Tsurutani, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Minato-Ku</city>
        <state>Tokyo</state>
        <zip>1058470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshimi Takano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <zip>2608717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naohito Yamamoto, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyusyu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>8111395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eriko Tokunaga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5400006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norikazu Masuda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenji Tamura, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Yun Kang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jee Hyun Kim, MD, MS, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Hun Lee, MS, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Soeul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyuk Sohn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Sim Yap, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Cancer Center</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Ching Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast Cancer</keyword>
  <keyword>palbociclib (PD-0332991)</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>goserelin</keyword>
  <keyword>any menopausal status</keyword>
  <keyword>hormone receptor positive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>locally advanced</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

